A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination with Androgen Receptor Pathway Inhibitors in Participants with Metastatic Hormone-sensitive Prostate Cancer

Status: Recruiting

Eligibility Criteria

Sex: Male
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of metastatic adenocarcinoma of the prostate - started androgen deprivation therapy (ADT) (luteinising hormone-releasing hormone [LHRH] agonist/antagonist or orchiectomy) with or without androgen receptor pathway inhibitor (ARPI) (pre-enrollment treatment with enzalutamide, abiraterone, apalutamide, or darolutamide are allowed). - first treatment with ADT should be no longer than 12 weeks before starting the study - see link to clinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- history of central nervous system (CNS) metastases - autoimmune disease requiring systemic treatment in the past 2 years - prior radiotherapy (to the prostate and/or to all visible metastatic lesions; palliative radiation within 2 weeks prior to first dose of study treatment is allowed - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), Metastatic Hormone-sensitive Prostate Cancer, mHSPC, prostate cancer

More Information

Description: The main goal of this study is to see if it's safe for people to take xaluritamig together with either darolutamide or abiraterone.
Study Contact: Nicholas Zorko - zorko004@umn.edu
Principal Investigator: Nicholas Zorko
Phase: PHASE1
IRB Number: STUDY00025859